AMLN (DIABETES DRUGS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: D.Right who wrote (889)	10/21/1997 8:41:00 AM
From: Henry Niman	of 2173

Dan, The price per share that LLY will pay for LGND is based on September prices (a 20% premium and LLY's stock will be locked up). It has nothing to do with LGND's current or future price. The deal is being widely published in news articles that came out after the close. LLY is making a big deal about the contribution to its pipeline. The deal is in focus articles on LLY as well as various versions of LLY's financials. LLY's financials have been flat in the diabetes area. The LGND deal will provode severaloral plays. In addition, their new osteoporosis drug, Evista (Raloxifene) is getting much coverage (on CNBC again this morning) and the deal also targets natural partners for that compound also. I don't think that many on this board think that AMLN's price is "capped" by the major discount JNJ received as part of its loan to AMLN (wasn't it something like an option to buy AMLN in 10 years for low double digits?).

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next